Search results for " Large"

showing 10 items of 392 documents

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R)…

2021

Context Tafasitamab+LEN, a chemotherapy-free, novel treatment for R/R DLBCL, demonstrated efficacy in ASCT-ineligible patients in the single-arm Phase II L-MIND study (NCT02399085). Objective To compare outcomes in patients treated with tafasitamab+LEN in the L-MIND study with matched patient populations treated with commonly administered NCCN-/ESMO-recommended therapies for non-transplant-eligible patients with R/R DLBCL in routine clinical practice. Design RE-MIND2 (NCT04150328) is an observational, retrospective cohort study. The L-MIND tafasitamab+LEN cohort was matched with RE-MIND2 patients using estimated propensity score-based 1:1 nearest neighbor matching balanced for nine patient …

BendamustineOncologyCancer Researchmedicine.medical_specialtybusiness.industryContext (language use)Retrospective cohort studyHematologymedicine.diseaseOncologyInternal medicineCohortmedicineClinical endpointRituximabbusinessDiffuse large B-cell lymphomamedicine.drugLenalidomideClinical Lymphoma Myeloma and Leukemia
researchProduct

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas

2007

AbstractIntegrative genomic and gene-expression analyses have identified amplified oncogenes in B-cell non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor suppressor genes within homozygous deletions remains unexplored. Array-based comparative genomic hybridization (CGH) and gene-expression microarray analysis of 48 cell lines derived from patients with different B-NHLs delineated 20 homozygous deletions at 7 chromosome areas, all of which contained tumor suppressor gene targets. Further investigation revealed that only a fraction of primary biopsies presented inactivation of these genes by point mutation or intragenic deletion, but instead some of them w…

BiopsyDNA Mutational AnalysisGene DosageVesicular Transport ProteinsApoptosisBiochemistryEpigenesis Geneticimmune system diseaseshemic and lymphatic diseasesChromosomes HumanGenes Tumor SuppressorPromoter Regions GeneticSorting NexinsOligonucleotide Array Sequence AnalysisSequence DeletionBcl-2-Like Protein 11HomozygoteChromosome MappingNuclear ProteinsNucleic Acid HybridizationRNA-Binding ProteinsHematologyDNA NeoplasmBCL10Gene Expression Regulation Neoplasticmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2DNA methylationLymphoma B-CellTumor suppressor geneImmunologyBiologyGene dosageCell Line TumorProto-Oncogene ProteinsmedicineCyclin-Dependent Kinase Inhibitor p18HumansPoint MutationGene SilencingB cellAdaptor Proteins Signal TransducingHomeodomain ProteinsMembrane ProteinsCell BiologyDNA Methylationmedicine.diseaseMolecular biologyLymphomaCancer researchMantle cell lymphomaApoptosis Regulatory ProteinsCarrier ProteinsDiffuse large B-cell lymphomaTranscription Factors
researchProduct

MEDLEM database, a data collection on large Elasmobranchs in the Mediterranean and Black seas

2020

The Mediterranean Large Elasmobranchs Monitoring (MEDLEM) database contains more than 3,000 records (with more than 4,000 individuals) of large elasmobranch species from 21 different countries around the Mediterranean and Black seas, observed from 1666 to 2017. The principal species included in the archive are the devil ray (1,868 individuals), the basking shark (935 individuals), the blue shark (622 individuals), and the great white shark (342 individuals). In the last decades, other species such as the thresher shark (187 individuals), the shortfin mako (180 individuals), and the spiny butterfly ray (138) were reported with increasing frequency. This was possibly due to increased public a…

Bycatch; databases; geographical distribution; large elasinobranchs; Mediterranean and Black seas; sharks0106 biological sciencesMediterranean climate2417.05 Biología Marina2510.01 Oceanografía Biológicalarge elasmobranchsMediterranean and Black seascetorhinus-maximus gunnerusOceanographycomputer.software_genre01 natural sciencesBasking sharkPesqueríasThresher shark1st recordsbiologyDatabaseconservationBycatch; databases; geographical distribution; large elasmobranchs; Mediterranean and Black seas; sharks04 agricultural and veterinary sciencescarcharhinidaeGeographyMediterranean and black seacoastbasking sharkLarge elasmobranchcarcharodon-carcharias linnaeusEnvironmental Engineeringdatabases[SDE.MCG]Environmental Sciences/Global ChangesFishingSede Central IEOAquatic Sciencesharksplumbeus chondrichthyesDatabasesharks.biology.animal[SDV.BA.ZV]Life Sciences [q-bio]/Animal biology/Vertebrate Zoologysharks; by-catch; databases; large elasmobranchs; geographical distribution; Mediterranean and Black seasgeographical distributionBycatch ; databases ; geographical distribution ; large elasinobranchs ; Mediterranean and Black seas ; sharks14. Life underwaterEcology Evolution Behavior and Systematicslarge elasinobranchs010604 marine biology & hydrobiologybiology.organism_classificationlamniformes cetorhinidaeby-catchBycatchGreat white sharkBycatchButterfly ray040102 fisheries0401 agriculture forestry and fisheriesConservation status[SDE.BE]Environmental Sciences/Biodiversity and Ecologycomputer
researchProduct

Differences in Dendritic Cell Activation and Distribution After Intravenous, Intraperitoneal, and Subcutaneous Injection of Lymphoma Cells in Mice

2007

Dendritic cells (DCs) are key antigen-presenting cells (APCs) for initiating immune responses. However, in recent years, several groups have shown the defective function of DCs in tumor-bearing mice and in cancer patients. Our aim was to study the effects of lymphoma on DC differentiation and maturation and to assess the input of the tumor microenvironment and intravasation of tumor cells on DC precursors. EL-4 lymphoma cells were administrated via different routes (intraperitoneal, subcutaneous, and intravenous) and DC phenotype was investigated. Bone marrow-derived DCs and APCs obtained from the spleen were examined by flow cytometry, and immunohistochemical analysis of lymphoma, lungs, l…

CD86Tumor microenvironmentCD40biologybusiness.industryhemic and immune systemschemical and pharmacologic phenomenaSpleenDendritic cellmedicine.diseasemedicine.anatomical_structureImmune systemImmunologybiology.proteinMedicinebusinessAnaplastic large-cell lymphomaCD80
researchProduct

Search for anomalous production of events with two photons and additional energetic objects at CDF

2010

27 páginas, 17 figuras, 5 tablas.-- CDF Collaboration: et al.

COLLIDER DETECTORNuclear and High Energy PhysicsParticle physicsMEDIATED SUPERSYMMETRY-BREAKINGPhysics beyond the Standard ModelP(P)OVER-BAR COLLISIONSFOS: Physical sciencesElementary particleddc:500.2GAMMA PRODUCTION114 Physical sciences01 natural sciences7. Clean energyHigh Energy Physics - ExperimentMEDIATED SUPERSYMMETRY-BREAKING; CENTRAL ELECTROMAGNETIC CALORIMETER; ELECTROWEAK SYMMETRY-BREAKING; LARGE EXTRA DIMENSIONS; P(P)OVER-BAR COLLISIONS; COLLIDER DETECTOR; GAMMA PRODUCTION; ROOT-S=1.96 TEV; QCD; PYTHIA-5.7Nuclear physicsHigh Energy Physics - Experiment (hep-ex)13.85Rm; 13.85Qk; 18.80.-j; 14.80.Ly0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]PYTHIA-5.7010306 general physicsPhysicsMuonLuminosity (scattering theory)hep-ex010308 nuclear & particles physicsPhysicsLARGE EXTRA DIMENSIONSQCDCENTRAL ELECTROMAGNETIC CALORIMETERROOT-S=1.96 TEVLarge extra dimensionHigh Energy Physics::ExperimentELECTROWEAK SYMMETRY-BREAKINGCollider Detector at FermilabEvent (particle physics)Lepton
researchProduct

Measurement and interpretation of the $W$-pair cross-section in $e^+e^-$ interactions at 161 GeV

1997

In 1996 LEP ran at a centre-of-mass energy of 161~GeV, just above the threshold of W-pair production. DELPHI accumulated data corresponding to an integrated luminosity of $9.93 {\mathrm{~pb^{-1}}}$, and observed 29 events that are considered as candidates for W-pair production. From these, a cross-section for the doubly resonant $e^+e^-\to\mathrm{WW}$ process of $3.67~^{+0.97}_{-0.85} \pm 0.19{\mathrm{~pb}}$ has been measured. Within the Standard Model, this cross-section corresponds to a mass of the W-boson of ${\mathrm{80.40~\pm~0.44~(stat.)~\pm~0.09~(syst.) ~\pm 0.03~(LEP)~GeV}}/c^2$. Alternatively, if $m_{\mathrm{W}}$ is held fixed at its current value determined by other experiments, t…

COLLISIONSNuclear and High Energy PhysicsParticle physicsElectron–positron annihilation01 natural sciencesBOSON MASS; ROOT-S=1.8 TEV; COLLISIONS; COUPLINGSPartícules (Física nuclear)Standard ModelInterpretation (model theory)Nuclear physics0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsDetectors de radiacióDELPHIPhysicsLuminosity (scattering theory)010308 nuclear & particles physicsROOT-S=1.8 TEVCOUPLINGSLARGE ELECTRON POSITRON COLLIDERBOSON MASSCross section (geometry)PARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle Physics - ExperimentPhysics Letters B
researchProduct

Search for neutral heavy leptons produced in Z decays

1997

Weak isosinglet Neutral Heavy Leptons ($\nu_m$) have been searched for using data collected by the DELPHI detector corresponding to $3.3\times 10^{6}$ hadronic~Z$^{0}$ decays at LEP1. Four separate searches have been performed, for short-lived $\nu_m$ production giving monojet or acollinear jet topologies, and for long-lived $\nu_m$ giving detectable secondary vertices or calorimeter clusters. No indication of the existence of these particles has been found, leading to an upper limit for the branching ratio $BR($Z$^0\rightarrow \nu_m \overline{\nu})$ of about $1.3\times10^{-6}$ at 95\% confidence level for $\nu_m$ masses between 3.5 and 50 GeV/$c^2$. Outside this range the limit weakens rap…

COLLISIONSParticle physicsE+E ANNIHILATIONPhysics and Astronomy (miscellaneous)Electron–positron annihilationHadronMASSJet (particle physics)HIGH-ENERGY-PHYSICS; MONOJET PRODUCTION; E+E ANNIHILATION; MONTE-CARLO; BOSON; LIMITS; MASS; LEP; PERFORMANCE; COLLISIONSHIGH-ENERGY-PHYSICS01 natural sciences7. Clean energyMONOJET PRODUCTIONNuclear physicsLIMITSMONTE-CARLO0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsDELPHIBosonPhysics010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyBOSONLEPPERFORMANCELARGE ELECTRON POSITRON COLLIDERPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHILarge Electron–Positron ColliderPARTICLE PHYSICSHigh Energy Physics::ExperimentNeutrinoParticle Physics - ExperimentLepton
researchProduct

Abstract 4107: Targeted re-sequencing of neuroblastoma tumors reveals chromosomal rearrangements that involve the Anaplastic Lymphoma Kinase (ALK) ge…

2013

Abstract Neuroblastoma (NBL) is a cancer of early childhood arising from the developing sympathetic nervous system. NBL tumors display a broad clinical and biological heterogeneity, ranging from highly aggressive tumors with fatal outcome to tumors with spontaneous regression. Recurrent mutations are mainly only observed in Anaplastic Lymphoma Kinase (ALK), which is involved in the pathogenesis of both familiar and sporadic NBL. ALK encodes a tyrosine kinase receptor with importance in neuronal development and was initially characterized in anaplastic large cell lymphoma from a translocation leading to the NPM-ALK fusion protein. Subsequent studies show that additional ALK chimeras have bee…

Cancer ResearchChromosomal translocationBiologyAmpliconmedicine.diseaseFusion proteinMolecular biologyExonOncologyhemic and lymphatic diseasesNeuroblastomamedicineAnaplastic lymphoma kinaseKinase activityAnaplastic large-cell lymphomaCancer Research
researchProduct

Abstract LB-017: HSP110 sustains aberrant NFkB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization

2017

Abstract Diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoproliferative disorder of B lymphocytes accounting for 30 % of adult Non Hodgkin Lymphoma (NHL). Among DLBCL, Activated B Cell - DLBCL (ABC-DLBCL) is the most aggressive form and has a poor prognosis. Heat-shock proteins (HSPs) are molecular chaperons highly expressed in cancer cells and implicated in resistance to radio- and chemotherapy. Therefore, HSPs are envisioned as therapeutic targets in many cancers. Among the different HSPs, HSP110 has been recently identified as a pro-survival factor in germinal center-derived DLBCL (GC-DLBCL), through stabilization of the GC-DLBCL oncogene Bcl-6. Here, we have explored if HSP1…

Cancer ResearchOncogeneBiologymedicine.diseaseLymphoma[ SDV.CAN ] Life Sciences [q-bio]/CancerSmall hairpin RNAmedicine.anatomical_structureOncologyCell cultureimmune system diseaseshemic and lymphatic diseasesCancer cellmedicineCancer researchGene silencingDiffuse large B-cell lymphomaneoplasmsB cell
researchProduct

The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase

2005

Abstract Background The involvement of Heat Shock Proteins (HSP) in cancer development and progression is a widely debated topic. The objective of the present study was to evaluate the presence and expression of HSP60 and HSP10 in a series of large bowel carcinomas and locoregional lymph nodes with and without metastases. Methods 82 Astler and Coller's stage C2 colorectal cancers, of which 48 well-differentiated and 34 poorly-differentiated, were selected along with 661 lymph nodes, including 372 with metastases and 289 with reactive hyperplasia only, from the same tumours. Primitive tumours and both metastatic and reactive lymph nodes were studied; specifically, three different compartment…

Cancer ResearchPathologymedicine.medical_specialtyTime FactorsColonColorectal cancerBlotting Westernlcsh:RC254-282Surgical oncologyIntestinal NeoplasmsBiomarkers TumorChaperonin 10GeneticsmedicineCarcinomaHumansIntestine LargeNeoplasm MetastasisStage (cooking)Lymph nodeInflammationAnalysis of VarianceHyperplasiabusiness.industryCarcinomaCell DifferentiationChaperonin 60Hyperplasialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyLymphatic MetastasisDisease ProgressionImmunohistochemistryhspLymph NodesLymphbusinessResearch ArticleBMC Cancer
researchProduct